The Brookbush Institute continues to enhance education with new articles, new courses, a modern glossary, an AI Tutor, ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Japan approves world-first iPS cell therapies for heart failure, Parkinsons Conditional approvals speed Japans first iPS treatments into clinics for heart failure and Parkinsons ...

Just in time for Heart Month, the laboratory of University de Montréal medical professor and CHU Sainte-Justine researcher Rubén Marín‑Juez has unveiled the first comprehensive atlas of coronary ...

For a heart just damaged by a blocked artery, timing matters. So does access. That is what makes a new experimental treatment ...

More than 300,000 people suffer a heart attack in Germany every year. The heart muscle is then no longer supplied with sufficient blood and oxygen, and part of the tissue dies and scars. Unlike the ...

Scientists have created a three-dimensional "heart-on-a-chip" (HOC) model that beats on its own, uses calcium to initiate ...

"Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD," said Michael Amoroso, Chief Executive Officer of Precision BioSciences. "We ...

A conserved glucagon signaling pathway links high-fat diet-induced metabolic imbalance to cardiac arrhythmia through hormone-producing cells and heart-innervating neurons that regulate rhythmicity.

The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...